Shares of Calithera Biosciences Inc (NASDAQ:CALA) have been assigned an average rating of “Hold” from the nine research firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $15.17.

A number of analysts recently weighed in on CALA shares. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Monday, November 6th. William Blair started coverage on shares of Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating on the stock. BidaskClub upgraded shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, August 18th. Finally, ValuEngine downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Friday.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of CALA. State Street Corp increased its stake in Calithera Biosciences by 5,802.1% during the 2nd quarter. State Street Corp now owns 1,304,375 shares of the biotechnology company’s stock worth $19,370,000 after purchasing an additional 1,282,275 shares in the last quarter. FMR LLC increased its stake in Calithera Biosciences by 85.8% during the 2nd quarter. FMR LLC now owns 2,717,090 shares of the biotechnology company’s stock worth $40,349,000 after purchasing an additional 1,254,900 shares in the last quarter. Vanguard Group Inc. increased its stake in Calithera Biosciences by 99.8% during the 1st quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after purchasing an additional 462,137 shares in the last quarter. Northern Trust Corp increased its stake in Calithera Biosciences by 1,355.1% during the 2nd quarter. Northern Trust Corp now owns 337,640 shares of the biotechnology company’s stock worth $5,014,000 after purchasing an additional 314,436 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Calithera Biosciences by 272.8% during the 3rd quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock worth $6,690,000 after purchasing an additional 310,806 shares in the last quarter. 72.19% of the stock is owned by institutional investors and hedge funds.

Shares of Calithera Biosciences (NASDAQ CALA) traded up $0.25 during trading hours on Thursday, hitting $10.00. 429,827 shares of the company were exchanged, compared to its average volume of 743,797. Calithera Biosciences has a 1-year low of $2.90 and a 1-year high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.02 million. research analysts predict that Calithera Biosciences will post -0.77 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/brokerages-set-calithera-biosciences-inc-cala-pt-at-15-17/1746139.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.